Merck’s Keytruda fails in Phase III triple-negative breast cancer study, but has a few more chances
The KEYNOTE-119 study failed to show a survival benefit in TNBC patients. The news comes two months after the FDA gave accelerated approval to a rival, Roche's Tecentriq.
